NCT07312045 HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy
| NCT ID | NCT07312045 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ömer Faruk Okumuş |
| Condition | Periodontal Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2026-11-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2025-11-25 with a primary completion date of 2026-11-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte / Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and salivary MMP-8 levels in individuals with periodontal health, gingivitis, and stage III/IV periodontitis. The study also evaluates how these biomarkers relate to healing following non-surgical periodontal therapy. A total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III/IV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit. The primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-65 years * Ability to provide informed consent * No systemic diseases or conditions affecting periodontal status * For Healthy Group: Probing depth ≤3 mm, no attachment loss, no radiographic bone loss * For Gingivitis Group: Gingival inflammation and bleeding on probing without attachment loss or bone loss * For Periodontitis Group: Stage III or stage IV periodontitis according to 2018 classification * No periodontal treatment within the past 6 months * Willingness to attend follow-up visits Exclusion Criteria: * Systemic diseases influencing periodontal inflammation (e.g., diabetes, autoimmune disorders) * Current pregnancy or lactation * Use of antibiotics, anti-inflammatory medications, or immunosuppressive drugs within the last 3 months * Smokers or individuals using tobacco products * History of periodontal surgery in the last 6 months * Presence of fewer than 20 natural teeth * Any condition that may interfere with study participation or data reliability
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07312045 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Periodontal Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07312045 currently recruiting?
Yes, NCT07312045 is actively recruiting participants. Contact the research team at okumus.omer24@gmail.com for enrollment information.
Where is the NCT07312045 trial being conducted?
This trial is being conducted at Merkez, Turkey (Türkiye).
Who is sponsoring the NCT07312045 clinical trial?
NCT07312045 is sponsored by Ömer Faruk Okumuş. The trial plans to enroll 180 participants.